PL340800A1 - Application of quinazoline derivatives as inhibitors of thyrosinic kinase in treating colonic polyps - Google Patents

Application of quinazoline derivatives as inhibitors of thyrosinic kinase in treating colonic polyps

Info

Publication number
PL340800A1
PL340800A1 PL98340800A PL34080098A PL340800A1 PL 340800 A1 PL340800 A1 PL 340800A1 PL 98340800 A PL98340800 A PL 98340800A PL 34080098 A PL34080098 A PL 34080098A PL 340800 A1 PL340800 A1 PL 340800A1
Authority
PL
Poland
Prior art keywords
thyrosinic
kinase
inhibitors
application
quinazoline derivatives
Prior art date
Application number
PL98340800A
Inventor
Philip Frost
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of PL340800A1 publication Critical patent/PL340800A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL98340800A 1997-11-06 1998-11-04 Application of quinazoline derivatives as inhibitors of thyrosinic kinase in treating colonic polyps PL340800A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96508497A 1997-11-06 1997-11-06

Publications (1)

Publication Number Publication Date
PL340800A1 true PL340800A1 (en) 2001-02-26

Family

ID=25509419

Family Applications (1)

Application Number Title Priority Date Filing Date
PL98340800A PL340800A1 (en) 1997-11-06 1998-11-04 Application of quinazoline derivatives as inhibitors of thyrosinic kinase in treating colonic polyps

Country Status (15)

Country Link
EP (1) EP1039910A1 (en)
JP (1) JP2001522802A (en)
KR (1) KR20010031813A (en)
CN (1) CN1278176A (en)
AR (1) AR016415A1 (en)
AU (1) AU1308799A (en)
BR (1) BR9814116A (en)
CA (1) CA2306155A1 (en)
HU (1) HUP0004286A3 (en)
IL (1) IL135622A0 (en)
NO (1) NO20002166L (en)
NZ (1) NZ503991A (en)
PL (1) PL340800A1 (en)
WO (1) WO1999024037A1 (en)
ZA (1) ZA9810134B (en)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL353267A1 (en) * 1999-08-12 2003-11-03 American Cyanamid Company Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
JP4724657B2 (en) 2003-05-30 2011-07-13 アストラゼネカ ユーケー リミテッド process
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
CN1972688B (en) 2004-05-06 2012-06-27 沃尼尔·朗伯有限责任公司 4-phenylamino-quinazolin-6-yl-amides
EP1838712B8 (en) 2004-12-14 2011-10-12 AstraZeneca AB Pyrazolopyrimidine compounds as antitumor agents
WO2006071079A1 (en) * 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
WO2007034144A1 (en) 2005-09-20 2007-03-29 Astrazeneca Ab 4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
US20100008910A1 (en) 2006-09-12 2010-01-14 John Chant Methods and compositions for the diagnosis and treatment of cancer
EP1921070A1 (en) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
EP2118075A1 (en) 2007-02-06 2009-11-18 Boehringer Ingelheim International GmbH Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
US20110104166A1 (en) 2008-01-18 2011-05-05 Stankovic Konstantina M Methods and Compositions for Treating Polyps
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
CA2711582A1 (en) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles, formulations containing said compounds, use thereof and processes for the preparation thereof
EP2303276B1 (en) 2008-05-13 2013-11-13 AstraZeneca AB Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
US8426430B2 (en) * 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
CN104447995A (en) 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 Bispecific anti-HER antibodies
KR20120103587A (en) 2009-11-12 2012-09-19 제넨테크, 인크. A method of promoting dendritic spine density
EP2523957A1 (en) 2010-01-12 2012-11-21 F. Hoffmann-La Roche AG Tricyclic heterocyclic compounds, compositions and methods of use thereof
DK2536748T3 (en) 2010-02-18 2014-10-13 Genentech Inc NEUREGULIN ANTAGONISTS AND ITS USE IN TREATMENT OF CANCER
CA2793024A1 (en) 2010-03-17 2011-09-22 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
MX2012011887A (en) 2010-04-16 2012-11-30 Genentech Inc Fox03a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy.
KR20130103734A (en) 2010-08-31 2013-09-24 제넨테크, 인크. Biomarkers and methods of treatment
MX2013003019A (en) 2010-09-15 2013-05-28 Hoffmann La Roche Azabenzothiazole compounds, compositions and methods of use.
MX2013005445A (en) 2010-11-19 2013-07-29 Hoffmann La Roche Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors.
WO2012085176A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
CN103889976A (en) 2011-08-12 2014-06-25 弗·哈夫曼-拉罗切有限公司 Indazole compounds, compositions and methods of use
US20140363438A1 (en) 2011-08-17 2014-12-11 Genentech, Inc. Neuregulin antibodies and uses thereof
JP2014526538A (en) 2011-09-20 2014-10-06 エフ．ホフマン−ラ ロシュ アーゲー Imidazopyridine compounds, compositions and methods of use
RU2014126098A (en) 2011-11-30 2016-01-27 Дженентек, Инк. Mutations of ErbB3 in Cancer
RU2014136886A (en) 2012-03-27 2016-05-20 Дженентек, Инк. DIAGNOSTIC AND TREATMENT TYPES RELATED TO HER3 INHIBITORS
EP2958592A1 (en) 2013-02-22 2015-12-30 F. Hoffmann-La Roche AG Methods of treating cancer and preventing drug resistance
KR20150123250A (en) 2013-03-06 2015-11-03 제넨테크, 인크. Methods of treating and preventing cancer drug resistance
WO2014139326A1 (en) 2013-03-13 2014-09-18 Genentech, Inc. Pyrazolo compounds and uses thereof
KR20150127216A (en) 2013-03-14 2015-11-16 제넨테크, 인크. Methods of treating cancer and preventing cancer drug resistance
JP2016515132A (en) 2013-03-14 2016-05-26 ジェネンテック， インコーポレイテッド Combination and use of MEK inhibitor compounds with HER3 / EGFR inhibitor compounds
WO2014144850A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
MX2016002794A (en) 2013-09-05 2016-09-13 Genentech Inc Antiproliferative compounds.
TW201605857A (en) 2013-10-03 2016-02-16 赫孚孟拉羅股份公司 Therapeutic inhibitors of CDK8 and uses thereof
CN105744954B (en) 2013-10-18 2021-03-05 豪夫迈·罗氏有限公司 anti-RSPO 2 and/or anti-RSPO 3 antibodies and uses thereof
WO2015095404A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancers using pd-1 axis binding antagonists and taxanes
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
EP3126394B1 (en) 2014-03-31 2019-10-30 F.Hoffmann-La Roche Ag Anti-ox40 antibodies and methods of use
RU2016142476A (en) 2014-03-31 2018-05-07 Дженентек, Инк. COMBINED THERAPY, INCLUDING ANTI-ANGIOGENESIS AGENTS AND AGONISTS BINDING OX40
EP3189046B1 (en) 2014-09-05 2020-08-26 Genentech, Inc. Therapeutic compounds and uses thereof
WO2016044694A1 (en) 2014-09-19 2016-03-24 Genentech, Inc. Use of cbp/ep300 and bet inhibitors for treatment of cancer
EP3204379B1 (en) 2014-10-10 2019-03-06 Genentech, Inc. Pyrrolidine amide compounds as histone demethylase inhibitors
MX2017005751A (en) 2014-11-03 2018-04-10 Genentech Inc Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment.
EP3215850B1 (en) 2014-11-03 2019-07-03 F. Hoffmann-La Roche AG Assays for detecting t cell immune subsets and methods of use thereof
KR20170072343A (en) 2014-11-06 2017-06-26 제넨테크, 인크. Combination therapy comprising ox40 binding agonists and tigit inhibitors
WO2016077375A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Bromodomain inhibitors and uses thereof
MA40943A (en) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS
MA40940A (en) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS
MX2017006320A (en) 2014-11-17 2017-08-10 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists.
US9763922B2 (en) 2014-11-27 2017-09-19 Genentech, Inc. Therapeutic compounds and uses thereof
BR112017010788A2 (en) 2014-12-23 2017-12-26 Genentech Inc methods of identifying a cancer patient and identifying a cancer patient who may benefit from administration of a vegf antagonist, method of treating a cancer patient, and method for determining ovarian cancer stage
JP2018503373A (en) 2014-12-30 2018-02-08 ジェネンテック， インコーポレイテッド Methods and compositions for cancer prognosis and treatment
EP3242874B1 (en) 2015-01-09 2018-10-31 Genentech, Inc. Pyridazinone derivatives and their use in the treatment of cancer
EP3242872B1 (en) 2015-01-09 2019-07-03 Genentech, Inc. (piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer
EP3242875B1 (en) 2015-01-09 2022-02-23 Genentech, Inc. 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
EP3250571B1 (en) 2015-01-29 2022-11-30 Genentech, Inc. Therapeutic compounds and uses thereof
WO2016123387A1 (en) 2015-01-30 2016-08-04 Genentech, Inc. Therapeutic compounds and uses thereof
MA41598A (en) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc PYRIDAZINE THERAPEUTIC COMPOUNDS AND THEIR USES
AU2016246695A1 (en) 2015-04-07 2017-10-26 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
RS61152B2 (en) 2015-05-12 2024-06-28 Hoffmann La Roche Therapeutic and diagnostic methods for cancer
JP7144935B2 (en) 2015-05-29 2022-09-30 ジェネンテック， インコーポレイテッド Therapeutic and diagnostic methods for cancer
KR20180011839A (en) 2015-06-08 2018-02-02 제넨테크, 인크. Treatment of Cancer Using Anti-OX40 Antibody
HK1251474A1 (en) 2015-06-08 2019-02-01 豪夫迈‧罗氏有限公司 Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
JP6896650B2 (en) 2015-06-17 2021-06-30 ジェネンテック， インコーポレイテッド Treatment of Locally Advanced or Metastatic Breast Cancer Using PD-1 Axle Antagonists and Taxanes
DK3341376T3 (en) 2015-08-26 2021-03-29 Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio CONDENSED TRICYCLIC COMPOUNDS AS PROTEINKINASE INHIBITORS
CA2994858C (en) 2015-09-25 2024-01-23 Genentech, Inc. Anti-tigit antibodies and methods of use
PL3978500T3 (en) 2015-12-16 2024-03-11 Genentech, Inc. Process for the preparation of tricyclic pi3k inhibitor compounds
JP6949030B2 (en) 2016-01-08 2021-10-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Treatment of CEA-Positive Cancer Using PD-1 Axial Binding Antagonists and Anti-CEA / Anti-CD3 Bispecific Antibodies
JP6821693B2 (en) 2016-02-29 2021-01-27 ジェネンテック， インコーポレイテッド Treatment and diagnosis for cancer
EP3443004A1 (en) 2016-04-14 2019-02-20 H. Hoffnabb-La Roche Ag Anti-rspo3 antibodies and methods of use
WO2017180581A1 (en) 2016-04-15 2017-10-19 Genentech, Inc. Diagnostic and therapeutic methods for cancer
CN109154613A (en) 2016-04-15 2019-01-04 豪夫迈·罗氏有限公司 For monitoring and the method for the treatment of cancer
AU2017248766A1 (en) 2016-04-15 2018-11-01 Genentech, Inc. Methods for monitoring and treating cancer
EP3464286B1 (en) 2016-05-24 2021-08-18 Genentech, Inc. Pyrazolopyridine derivatives for the treatment of cancer
MA45122A (en) 2016-05-24 2019-04-10 Constellation Pharmaceuticals Inc CBP / EP300 HETEROCYCLIC INHIBITORS AND THEIR USE IN CANCER TREATMENT
US20200129519A1 (en) 2016-06-08 2020-04-30 Genentech, Inc. Diagnostic and therapeutic methods for cancer
US11046776B2 (en) 2016-08-05 2021-06-29 Genentech, Inc. Multivalent and multiepitopic antibodies having agonistic activity and methods of use
WO2018029124A1 (en) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
AU2017339517B2 (en) 2016-10-06 2024-03-14 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
EP3532091A2 (en) 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic antibidies and methods of use
CN110546277B (en) 2017-03-01 2024-06-11 豪夫迈·罗氏有限公司 For diagnosis and treatment of cancer
KR20190136076A (en) 2017-04-13 2019-12-09 에프. 호프만-라 로슈 아게 Interleukin-2 immunoconjugates, CD40 agonists and optional PD-1 axis binding antagonists for use in cancer treatment methods
KR102922386B1 (en) 2017-07-21 2026-02-04 제넨테크, 인크. Therapeutic and diagnostic methods for cancer
AU2018329925B2 (en) 2017-09-08 2025-05-29 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for cancer
WO2019084395A1 (en) 2017-10-27 2019-05-02 University Of Virginia Patent Foundation Compounds and methods for regulating, limiting, or inhibiting avil expression
ES2984919T3 (en) 2017-11-06 2024-10-31 Hoffmann La Roche Diagnostic and therapeutic procedures for cancer
AU2019207535B2 (en) 2018-01-15 2021-12-23 Epiaxis Therapeutics Pty Ltd Agents and methods for predicting response to therapy
CN112771177A (en) 2018-05-21 2021-05-07 纳米线科技公司 Molecular gene tags and methods of use thereof
CN112585166A (en) 2018-06-23 2021-03-30 豪夫迈·罗氏有限公司 Methods of treating lung cancer with PD-1 axis binding antagonists, platinating agents, and topoisomerase II inhibitors
BR112021000673A2 (en) 2018-07-18 2021-04-20 Genentech, Inc. methods for treating an individual with lung cancer, kits, anti-pd-l1 antibody and compositions
WO2020051099A1 (en) 2018-09-03 2020-03-12 Genentech, Inc. Carboxamide and sulfonamide derivatives useful as tead modulators
JP2022501332A (en) 2018-09-19 2022-01-06 ジェネンテック， インコーポレイテッド How to treat and diagnose bladder cancer
KR102739487B1 (en) 2018-09-21 2024-12-10 제넨테크, 인크. Diagnostic methods for triple-negative breast cancer
US12404540B2 (en) 2018-10-17 2025-09-02 The University Of Queensland Epigenetic biomarker and uses therefor
MX2021004348A (en) 2018-10-18 2021-05-28 Genentech Inc DIAGNOSTIC AND THERAPEUTIC PROCEDURES FOR SARCOMATOID KIDNEY CANCER.
EP3921443A1 (en) 2019-02-08 2021-12-15 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for cancer
EP3931565A4 (en) 2019-02-27 2023-04-12 Epiaxis Therapeutics Pty Ltd METHODS AND AGENTS FOR ASSESSING T LYMPHOCYTE FUNCTION AND PREDICTING RESPONSE TO THERAPY
KR20210133237A (en) 2019-02-27 2021-11-05 제넨테크, 인크. Dosing for treatment with anti-TIGIT and anti-CD20 or anti-CD38 antibodies
WO2020223233A1 (en) 2019-04-30 2020-11-05 Genentech, Inc. Prognostic and therapeutic methods for colorectal cancer
CN114269376A (en) 2019-05-03 2022-04-01 豪夫迈·罗氏有限公司 Methods of treating cancer with anti-PD-L1 antibodies
CN112300279A (en) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 Methods and compositions directed to anti-CD 73 antibodies and variants
WO2021046159A1 (en) 2019-09-04 2021-03-11 Genentech, Inc. Cd8 binding agents and uses thereof
EP4048693A1 (en) 2019-09-27 2022-08-31 F. Hoffmann-La Roche AG Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
EP4051674A1 (en) 2019-10-29 2022-09-07 F. Hoffmann-La Roche AG Bifunctional compounds for the treatment of cancer
AU2020378330A1 (en) 2019-11-06 2022-05-12 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for treatment of hematologic cancers
CN114728905B (en) 2019-11-13 2025-08-01 基因泰克公司 Therapeutic compounds and methods of use
WO2021119505A1 (en) 2019-12-13 2021-06-17 Genentech, Inc. Anti-ly6g6d antibodies and methods of use
EP4076667A1 (en) 2019-12-20 2022-10-26 Erasca, Inc. Tricyclic pyridones and pyrimidones
CN115315256A (en) 2020-01-27 2022-11-08 基因泰克公司 Methods of treating cancer with anti-TIGIT antagonist antibodies
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021177980A1 (en) 2020-03-06 2021-09-10 Genentech, Inc. Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
EP4127724A1 (en) 2020-04-03 2023-02-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
EP4143345A1 (en) 2020-04-28 2023-03-08 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
MX2022015877A (en) 2020-06-16 2023-01-24 Genentech Inc Methods and compositions for treating triple-negative breast cancer.
CN115916348A (en) 2020-06-18 2023-04-04 基因泰克公司 Treatment with Anti-TIGIT Antibodies and PD-1 Axis Binding Antagonists
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
EP4189121A1 (en) 2020-08-03 2023-06-07 Genentech, Inc. Diagnostic and therapeutic methods for lymphoma
EP4196612A1 (en) 2020-08-12 2023-06-21 Genentech, Inc. Diagnostic and therapeutic methods for cancer
AU2021347232A1 (en) 2020-09-23 2023-04-27 Erasca, Inc. Tricyclic pyridones and pyrimidones
KR20230082632A (en) 2020-10-05 2023-06-08 제넨테크, 인크. Dosing for Treatment with Anti-FCRH5/Anti-CD3 Bispecific Antibodies
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
JP7821808B2 (en) 2021-02-12 2026-02-27 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Bicyclic tetrahydroazepine derivatives for the treatment of cancer
CA3221390A1 (en) 2021-05-25 2022-12-01 Erasca, Inc. Sulfur-containing heteroaromatic tricyclic kras inhibitors
US20240293558A1 (en) 2021-06-16 2024-09-05 Erasca, Inc. Kras inhibitor conjugates
WO2023018699A1 (en) 2021-08-10 2023-02-16 Erasca, Inc. Selective kras inhibitors
EP4436957A1 (en) 2021-11-24 2024-10-02 Genentech, Inc. Therapeutic indazole compounds and methods of use in the treatment of cancer
TW202340212A (en) 2021-11-24 2023-10-16 美商建南德克公司 Therapeutic compounds and methods of use
IL315770A (en) 2022-04-01 2024-11-01 Genentech Inc Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
CN119317641A (en) 2022-05-11 2025-01-14 基因泰克公司 Administration for treatment with anti-FCRH5/anti-CD3 bispecific antibodies
EP4537107A2 (en) 2022-06-07 2025-04-16 Genentech, Inc. Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody
JP2025523020A (en) 2022-07-13 2025-07-17 ジェネンテック， インコーポレイテッド Administration for Treatment with Anti-FcRH5/Anti-CD3 Bispecific Antibody
CA3261510A1 (en) 2022-07-19 2024-01-25 F. Hoffmann-La Roche Ag Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024033457A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
TW202417001A (en) 2022-08-11 2024-05-01 瑞士商赫孚孟拉羅股份公司 Bicyclic tetrahydroazepine derivatives
CR20250043A (en) 2022-08-11 2025-03-25 Hoffmann La Roche Bicyclic tetrahydrothiazepine derivatives
WO2024033388A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
JP2025538859A (en) 2022-10-21 2025-12-02 公益財団法人川崎市産業振興財団 Non-adsorbing or super stealth vesicles
WO2024091991A1 (en) 2022-10-25 2024-05-02 Genentech, Inc. Therapeutic and diagnostic methods for multiple myeloma
TW202434206A (en) 2023-02-17 2024-09-01 美商伊瑞斯卡公司 Kras inhibitors
WO2024233341A1 (en) 2023-05-05 2024-11-14 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
CN121285742A (en) 2023-06-08 2026-01-06 基因泰克公司 Macrophage characterization for diagnostic and therapeutic methods of lymphoma
WO2025024257A1 (en) 2023-07-21 2025-01-30 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2025049277A1 (en) 2023-08-25 2025-03-06 Genentech, Inc. Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist
WO2026030476A1 (en) 2024-07-30 2026-02-05 Genentech, Inc. Precision medicine for optimal dosage of combined therapies systems and methods of use thereof
WO2026030464A1 (en) 2024-07-30 2026-02-05 Genentech, Inc. Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors

Also Published As

Publication number Publication date
IL135622A0 (en) 2001-05-20
JP2001522802A (en) 2001-11-20
EP1039910A1 (en) 2000-10-04
HUP0004286A3 (en) 2002-01-28
ZA9810134B (en) 2000-05-05
NO20002166L (en) 2000-06-28
WO1999024037A1 (en) 1999-05-20
BR9814116A (en) 2000-10-03
HUP0004286A2 (en) 2001-11-28
NO20002166D0 (en) 2000-04-27
NZ503991A (en) 2001-11-30
AU1308799A (en) 1999-05-31
CA2306155A1 (en) 1999-05-20
KR20010031813A (en) 2001-04-16
AR016415A1 (en) 2001-07-04
CN1278176A (en) 2000-12-27

Similar Documents

Publication Publication Date Title
PL340800A1 (en) Application of quinazoline derivatives as inhibitors of thyrosinic kinase in treating colonic polyps
HUP0003194A3 (en) Use of tyrosine kinase inhibitor in synergic pharmaceutical composition treating prostate cancer
IL134013A (en) Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors
HUP0203323A3 (en) Tyrosine kinase inhibitors and pharmaceutical compositions containing them
HUP0203162A3 (en) Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
HUP0104752A3 (en) Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors and pharmaceutical compositions containing them
HUP0103520A3 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors and pharmaceutical compositions containing them
NO985652D0 (en) Use of naaladase inhibitors in the treatment of cancer
HUP0302615A3 (en) Kinase inhibitor quinazoline derivatives and pharmaceutical compositions containing them and their use
AP2000001861A0 (en) Bicylic heteroaromatic compounds as protein tyrosine kinase inhibitors
GB9501567D0 (en) Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
IL153246A0 (en) Substituted quinazoline derivatives and their use as inhibitors
HUP0202682A3 (en) Tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
HUP0004490A3 (en) Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threoning kinase inhibitors and pharmaceutical compositions containing them
HUP0300205A3 (en) Aurora 2 kinase inhibitor quinazoline derivatives, preparation and use thereof
PL352931A1 (en) Compositions and uses of et743 for treating cancer
HU0900792D0 (en) Use of renin-angiotensin inhibitors
PL329153A1 (en) Derivatives of pyrrolopyrolone as inhibitors of neutropil elastase
IL139490A0 (en) Phthalazine derivatives as phosphodiesterase 4 inhibitors
FI955661L (en) Substituted beta-aryl and beta-heteroaryl-alpha-cyanoacrylamide derivatives as tyrosine kinase inhibitors
IL134791A0 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
IL132094A0 (en) Methods and compositions for treatment of ovarian cancer
HUP0002249A3 (en) Use of pyrimidine and triazine derivatives for producing pharmaceutical compositions useful for treating cancer
HUP0003475A3 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
AU6906396A (en) Methods and compositions including dna damaging agents and tyrosine kinase inhibitors or activators